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The 52-aminoacid peptide adrenomedullin (AM) is expressed in the normal and malignant prostate. We have previously shown that prostate
cancer cells produce and secrete AM, which acts as an autocrine growth inhibitory factor. We have evaluated in the present study the role of AM in
prostate cancer cell apoptosis, induced either by serum deprivation or treatment with the chemotherapeutic agent etoposide (which acts as an
inhibitor of topoisomerase II). For this purpose we over-expressed AM in PC-3, DU 145 and LNCaP cells, which were transfected with an
expression vector carrying AM. We also treated the parental cell lines with synthetic AM in normal culture conditions and in conditions of
induced-apoptosis. After serum removal, AM prevented apoptosis in DU 145 and PC-3 cells, but not in LNCaP cells. When treated with
etoposide, AM prevented apoptosis in PC-3 and LNCaP cells, but not in DU 145 cells. Cell cycle analysis demonstrated a significant decrease in
the percentage of AM-overexpressing PC-3 cells in the subG0/G1 phase after treatment with etoposide, as compared to the percentage of mock-
transfected PC-3 treated cells. Western blot showed that protein levels of phosphorylated ERK1/2 increased in parental PC-3 cells after treatment
with etoposide. In PC-3 cells overexpressing AM, phosphorylated ERK1/2 basal levels were lower than basal levels of parental PC-3 cells, and
treatment with etoposide did not result in such an increase. Etoposide produced a significant increase in cleaved PARP in parental PC-3 cells.
However, PC-3 clones overexpressing AM that were treated with etoposide only showed a mild increase in fragmented PARP. The ratio Bcl-2/Bax
was reduced in parental or mock-transfected PC-3 cells after treatment with etoposide. On the contrary, this ratio was not reduced in PC-3 clones
with AM overexpression that were treated with etoposide. All these data demonstrate that AM plays a protective role against induced apoptosis in
prostate cancer cells. These results may have important implications in prostate cancer resistance to chemotherapeutic agents.
D 2005 Elsevier B.V. All rights reserved.Keywords: Adrenomedullin; Apoptosis; Bcl-2; Bax1. Introduction
Prostate cancer (PrCa) is a leading cause of cancer mortality
among men in western countries [1]. The incidence of PrCa has
increased during the last decade, due in part to aging of the
male population and the widespread use of screening tests [2].
Even though localized prostate cancer can be treated and cured,
there is no successful treatment for the advanced androgen-
independent metastatic disease [2]. Understanding molecular
mechanisms involved in androgen refractory tumor growth is a
hallmark of prostate cancer research. The finding of genes
whose expression is altered in androgen-independent prostate0167-0115/$ - see front matter D 2005 Elsevier B.V. All rights reserved.
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E-mail address: acalvo@unav.es (A. Calvo).cancer will provide additional targets for therapy. In this regard,
high throughput microarray analyses are currently providing
new gene candidates for such a purpose [3]. It has been
suggested that growth factors which regulate locally cell–cell
interactions, could play a key role in tumor growth after
androgen withdrawal [4]. We and others have previously
reported that adrenomedullin (AM), a 52-aminoacid peptide
isolated from a pheochromocytoma [5], is highly expressed in
the normal and malignant prostate [6–8]. Expression of AM in
LNCaP cells increases when androgens are removed from the
culture medium [9]. Our previous experiments in vivo using
androgen-dependent prostate tumors xenografted into nude
mice showed that the expression of AM increases after
castration [9]. Rocchi et al. [10] have shown an increase in
AM levels in LuCaP 23.1 xenografted tumors after castration.
Numerous roles have been attributed to AM in different
organs, such as vasodilation, bronchodilation, hormone secre-(2006) 115 – 122
www.e
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recently shown that AM causes cell growth inhibition in PC-3
and LNCaP prostate cancer cells and decreases tumor growth
in vivo in xenograft models [12,13]. We have also demon-
strated that overexpression of AM in PC-3 cells changes the
transcriptional program of approximately 100 genes compared
to the parental cells, including GADD45, IFG-BP6, RUNX3,
IL-13Ra2, IL-8, and tenascin C [14]. A group of 10
dysregulated genes were related to apoptosis, whereas other
genes were related to cell adhesion, extracellular matrix
proteins, and tumor-related cytokines [14].
Three receptors for AM have been described: L1, RDC1,
and the calcitonin receptor-like receptor (CL) coupled with the
receptor activity modifying proteins (RAMPs) [11]. Among
these, the CL/RAMPs complex seems to be the most important
one. CL requires the presence of RAMPs for intracellular
signaling [15]. RAMP-1 acts as a calcitonin gene related
protein (CRGP) and AM receptor when coupled with CL.
However, it binds with much more affinity to CGRP than to
AM [15]. RAMP-2 or RAMP-3 coupled with CL bind
specifically to AM [15]. PC-3, LNCaP and DU 145 express
the CL/RAMP-2 receptor complex [13], and AM acts as an
autocrine factor for these cells [13].
Several studies have shown that AM provides cells
protection from undergoing apoptosis. Such a result has been
demonstrated in breast cancer [16], endometrial cancer [17],
and endothelial [18] cells. Culture of cells under stressful
conditions, such as exposure to TNFa [19], hypoxia [17] or
serum deprivation [20,18] stimulates AM expression. Since our
previous publications showed that AM causes cell cycle arrest
and subsequent cell growth inhibition in PC-3 and LNCaP
cells, we hypothesized in the present study that AM would
favor cells to undergo induced-apoptosis. Our results turned
out to be opposite to this hypothesis. PC-3 or LNCaP cells
treated with AM plus etoposide, or cultured without serum plus
AM had a survival advantage with respect to untreated cells.
The same result was found for cells overexpressing AM.
Moreover, proteins of the apoptotic cascade were not as
induced in AM-overexpressing cells as in the parental cells. We
suggest that AM can have a dual role in prostate cancer cells
regulating differently cell growth (depending upon stress
culture conditions), and that AM can play a role against
resistance to chemotherapeutic drugs.
2. Materials and methods
2.1. Cell culture
Prostate cancer cell lines (PC-3, DU 145 and LNCaP) were
cultured in RPMI 1640 medium with Glutamax-I (Invitrogen,
Paisley, UK) supplemented with 10% fetal calf serum (FCS;
Invitrogen), 100 U/mL penicillin and 100 Ag/mL streptomycin
(Invitrogen) (complete medium). PC-3 and DU 145 cell clones
overexpressing AM were obtained by stable transfection of the
pcDNA3.1/Hygro/LacZ plasmid, and have been previously
established and characterized by our group [12,13]. Clones
were grown in the complete medium plus 150 Ag/mLhygromycin B (Invitrogen) for selection of the plasmid-
containing cells. For LNCaP cells, transient transfections were
used, since stably transfected clones lost expression of AM
after 1 week in culture [13].
2.2. MTT and cell cycle assays
Two methods for the induction of apoptosis were used: (a)
Culture of cells in serum-removed medium and (b) treatment
with etoposide (Sigma, Barcelona, Spain). Etoposide was
diluted in DMSO, so that the final concentration of DMSO
was less than 1% of the culture medium volume. For MTT
assays in serum-deprived conditions, 2.4104 cells/well were
plated in 96-well plates, in RPMI without FCS for 0, 24, 48 and
72 h. For MTT assays with etoposide, the same number of cells
was plated in RPMI with 10% FCS.
To test the effect of AM on cell proliferation, hAM
(Peninsula-Bachem, San Carlos, CA) was added daily to the
cell culture medium at a final concentration of 100 nM.
Treatment with etoposide was applied to the cells 24 h after
plating, at a concentration of 100 mg/L.
For cell cytometry analysis, synchronized cells were grown
for 24 h in complete medium, and then treated or untreated
with 100 mg/L etoposide for 24, 48 and 72 h. Cells were then
collected and processed with the DNA Prep Coulter kit
(Beckman Coulter, Fullerton, CA), following the manufac-
turer’s instructions. Cells were analyzed in a FacsCalibur flow
cytometer (Becton Dickinson) with a 488 nm excitation
wavelength.
2.3. Western blot
Protein extraction from cell lysates was performed in RIPA
buffer when antibodies anti-Bcl-2, -Bax, -PARP, and -h actin
were used. For phosphorylated and total ERK1/2 detection, the
lysis buffer consisted of: 25 mM sodium h-glycerolphosphate,
1 mM sodium orthovanadate, 25 mM NaF, 1 mM Na2P3O4, 1%
TritonX-100, 0.05% sodium deoxycholate, 1mM benzamidine,
10% glycerol, 0.1% h-mercaptoethanol, 0.01% SDS, 5 mM
EDTA, and 5 mM EGTA (all of them from Sigma, Steinheim,
Germany). Both extraction buffers contained a cocktail of
protease inhibitors (Completei; Roche Diagnostics, Penzberg,
Germany). Protein concentration was spectrophotometrically
measured using the BCAi protein assay kit (Pierce, Rockford,
IL, USA). Sixty micrograms of protein were loaded in each
well, which where separated by SDS-PAGE in 4–12% Bis–
Tris polyacrylamide pre-cast gels (Invitrogen). Tris-acetate gels
(Invitrogen) were used to detect PARP. Electrophoresis was
performed in the presence of 5% 2-h-mercaptoethanol for 45
min at 200 V. Proteins were transferred to a 0.22 Am
nitrocellulose membrane (BioRad, Hercules, CA) at 30V for
1 h, and membranes were stained with Ponc¸eau solution. Blots
were then incubated for 2 h at RT in blocking solution (Tropix,
Bedford, MA). Polyclonal anti-Bcl-2 and anti-Bax antibodies
(both from Santa Cruz) were used at 1:500 and 1:1000 dilution,
respectively. Polyclonal anti-PARP (Promega, Madison, WI)
was used at 1:5000 and monoclonal anti-h actin antibody
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Fig. 1. MTT assays of DU 145 (A) and PC-3 (B) prostate cell clones 24 h after
serum removal. A: DU 145 cell clones that overexpress AM (DU-AM9, DU-
AM6, and DU-AM11) show a significant increase in proliferation rates (**,
p <0.001) compared to control cells (DU 145 parental and DU-145 Mock1
cells). B: PC-3 clones with AM overexpression (PC-AM31, PC-AM32, and
PC-AM15) also show a significant growth advantage (*, p <0.05) with respect
to controls (PC-3, and PC-Mock2).
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Fig. 2. MTT assays of PC-3 (A) and LNCaP (B) prostate cells after treatment
with etoposide, or etoposide plus AM. A: The percentage of viable PC-3 cells
24 h and 48 h after treatment with etoposide is significantly higher when cells
are treated with AM. B: A similar result is found for LNCaP cells. Exposure to
AM plus etoposide provides a significant growth advantage ( p <0.05) over
cells treated with etoposide alone. **p <0.01; *p <0.05.
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phosporylated and total ERK1/2 (Cell Signaling, Beverly, MA)
were diluted at 1:1000. Incubation with the appropriate
secondary antibody and chemoluminiscence detection kit
(Tropix) were used for visualization of the signal.
3. Results
3.1. AM protects prostate cancer cells from apoptosis-induced
cell death
Two widely used methods to induce apoptosis in prostate
cancer cells are the depletion of serum in the culture medium
and treatment with etoposide. To evaluate whether AM wasinvolved in prostate cancer cell apoptosis we used cell clones
that overexpress AM, or exogenous treatment with the AM
peptide. We have previously generated and characterized PC-3
(AM15, AM32, AM31), DU 145 (AM6, AM9, AM11), and
LNCaP (LNCaP-AM) cells with high or intermediate expres-
sion of AM, and mock-transfected clones (Mock-2 for PC-3,
Mock-1 for DU 145, Mock-LNCaP for LNCaP cells) [13].
First, we compared cell viability of parental, mock-transfected
or AM-transfected clones in serum-deprived culture media.
Twenty-four hours after serum removal, cell viability was
significantly higher in DU 145 and PC-3 cell clones that
overexpressed AM, compared to the parental or mock-
transfected cells (Fig. 1). In LNCaP cells, however, over-
expression of AM did not modify cell viability when compared
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Fig. 3. Cell survival in PC-3 clones treated with etoposide for 24 h or 48 h. PC-
3 cell clones with high expression of AM (PC-AM32, and PC-AM15) show
significantly higher survival rates than controls (PC-3, and PC-Mock2).
**p <0.01.
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Fig. 4. Cell cycle analysis in PC-3 clones treated or untreated with etoposide.
The percentage of cells in the subG0/G1 phase (suggesting apoptosis) increases
dramatically when cells are treated with etoposide, irrespective of AM levels.
However, in clones overexpressing AM (PC-AM31 for (A); PC-AM32 for (B)),
such an increase is significantly lower (**p <0.01) than that found for control
cells (PC-3, and PC-Mock2), after treatment with this chemotherapeutic agent.
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shown).
Cell viability was also assessed in parental prostate cancer
cells treated with etoposide, or etoposide plus AM peptide.
Treatment with AM significantly prevented etoposide-induced
apoptosis in PC-3 and LNCaP cells (Fig. 2), but had no effect
in DU 145 cells (result not shown). The protective effect was
especially significant in PC-3 cells, whereas LNCaP cells
showed a milder cell growth advantage (Fig. 2). Parental PC-3,
mock-transfected and AM-overexpressing clones were also
treated with etoposide and tested for cell viability. Clones PC-
AM32 and PC-AM15, which expressed high levels of AM
showed a significant increase in cell viability as compared to
the parental or mock-transfected cells (Fig. 3).
We next conducted cell cycle analysis in PC-3 clones. The
percentage of cells in the subG0/G1 phase of the cell cycle
(which suggests apoptosis) was quantified in PC-3, mock-
transfected, and clones overexpressing AM (PC-AM31, and
PC-AM32), which were previously treated or untreated with
etoposide. Overexpression of AM resulted in a significant
decrease in the percentage of cells in the subG0/G1 phase
(Fig. 4).
3.2. AM increases the Bcl-2/Bax ratio and reduces phosphor-
ylated ERK1/2 levels in etoposide-treated cells
Because of the importance of etoposide as a chemothera-
peutic drug frequently used in patients with androgen-
independent prostate cancer, we further analyzed mechanisms
of AM-mediated protection against etoposide-induced apopto-
sis. PC-3 cells were selected for these assays because of their
androgen independence and for being more sensitive to AM
than DU 145 and LNCaP cells.
Intracellular levels of phosphorylated ERK1/2 (p-ERK1/2)
usually correlate with cell proliferation and survival [21].However, treatment of cancer cells with etoposide or other
genotoxic substances can also induce p-ERK1/2 [22,23]. We
have previously shown that overexpression of AM causes
decrease in p-ERK1/2 in PC-3 cells [13]. Treatment of parental
or mock-transfected PC-3 cells with etoposide resulted in an
increase in p-ERK1/2 without change in total ERK1/2 levels
(Fig. 5). In PC-3 clones with overexpression of AM, as
mentioned before, there was a decrease in p-ERK1/2 without
etoposide treatment. After incubation with etoposide, a mild
increase in p-ERK1/2 levels was observed in AM-overexpres-
sing clones. Nonetheless, such an increase was not as strong as
the increase found for the controls (Fig. 5). These results show
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Fig. 5. Effect of AM on the induction of p-ERK1/2, after treatment with etoposide. A: Parental cells treated with etoposide show an increase in p-ERK1/2 levels with
no change in total ERK1/2 levels. PC-3 clones with AM-overexpression (PC-AM15, and PC-AM32) have very low levels of p-ERK, as compared to parental cells.
When PC-AM15 or PC-AM32 clones are treated with etoposide, the induction of p-ERK1/2 levels is not as pronounced as the increase that was observed for the
parental cells. B: Densitometric quantification of the bands, normalization with h-actin, and calculation of the ratio p-ERK1/2/Total ERK1/2 confirmed the results.
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cells with high expression of AM.
The apoptotic effect of etoposide on PC-3 cells was
analyzed by cleaved PARP, Bcl-2 and Bax Western blotting
(Fig. 6). In control cells, a band of 85 kDa, corresponding to
fragmented PARP was found after treatment with etoposide
(Fig. 6). No signal was observed in untreated cells. In PC-3
clones with high expression of AM (PC-AM15 and PC-
AM32), the 85 kDa band was also found after exposure to
etoposide, but the intensity of the bands were significantly
weaker than that of controls (Fig. 6). This result shows that,
indeed, AM protects cells from induced apoptosis.
Bcl-2 protein was constitutively expressed in PC-3 cells.
Levels of Bcl-2 were decreased in parental PC-3 cells after
treatment with etoposide (Fig. 6). On the contrary, Bax was up-
regulated after incubation with etoposide (Fig. 6). Therefore,
the Bcl-2/Bax ratio in PC-3 cells treated with etoposide
decreased as compared to the ratio observed for untreated
parental cells. A similar result was observed for PC-3 cells
transfected with the empty vector (PC-Mock2) (Fig. 6). When
the AM-overexpressing PC-3AM15 and PC-AM32 clones
were treated with etoposide, no such a reduction of Bcl-2 nor
induction of Bax were observed (Fig. 6). Therefore, the Bcl-2/
Bax ratio remains high, as opposed to the parental or mock-
transfected cells (Fig. 6). These results show protection against
pro-apoptotic signalling in PC-3 cells overexpressing AM.
4. Discussion
A previous study from our group showed that adrenome-
dullin causes anti-mitogenic effects and cell cycle growth arrest
in PC-3 and LNCaP prostate cancer cells, when cells are grownin serum-containing culture medium [13]. The same result was
found when AM levels were kept constantly elevated after
stable transfection of an expression vector. Moreover, tumor
volume was significantly reduced (by 50%) in nude mice
injected with PC-3 clones overexpressing AM, compared to
controls (either the parental cells or cells stably transfected with
the empty plasmid). Adrenomedullin seemed to act through an
autocrine loop in these cells to produce such an effect, since
they express both AM and the AM receptor complex CL/
RAMP-2 [13].
We have previously shown as well by microarray analyses
that overexpression of AM in PC-3 cells leads to changes in the
transcriptional program of approximately 100 genes, among
which there were many related to cell cycle arrest and
apoptosis [14]. AM overexpression resulted in increased
mRNA levels of GADD45A, IGF-BP6, STK-17, Bcl-2-related
protein A1, 5V-nucleotidase (CD-73), TNF-a induced protein,
and RUNX3 transcripts. These results are in agreement with
the cell inhibitory effect that we described previously. In view
of these results, we hypothesized in the present study that AM
could sensitize prostate cells to undergo apoptosis. Our work
here shows an opposite result than we expected. Indeed,
prostate cancer cells that overexpress AM, or are treated
exogenously with an AM peptide are more refractory to
undergo apoptosis than control cells.
The first method used to induce programmed cell death was
the removal of serum from the culture medium, which gets rid
of growth factors and results in the inability of cells to pass
through the G1 restriction point and entering in the cell cycle
[24]. The second method consisted of treating the cells with
etoposide, which is a topoisomerase II inhibitor [25,26]. We
have found that AM protects prostate cancer cells from
Etoposide
(100 mg/L)
PC-3 PC-Mock2 PC-AM15 PC-AM32
- +       - +    - +       - +
Bcl-2
-actin
28 kDa
Bax
-actin
Ratio Bcl-2/ Bax
21 kDa
Etoposide
(100 mg/L)
PC-Mock2 PC-AM15 PC-AM32
- +        - +       - +
85 kDaCleaved PARP
A
B
0
2
4
6
8
10
12
1 2 3 4 5 6 7 8
PC-3 clones
R
at
io
 B
cl
-2
 / 
Ba
x
C
PC
-3
 (-
)
(10.7)
PC
-3
 (+
)
(1.1)
M
oc
k 
(-)
M
oc
k 
(+)
(7.2) (1.8)
A
M
-1
5 
(-)
A
M
-1
5 
(+)
(6.1) (6.3)
A
M
-3
2 
(-)
A
M
-3
2 
(+)
(9.7) (5.3)
β
β
Fig. 6. Effect of AM on apoptosis. A: After exposure to etoposide, Western blot for cleaved PARP shows a strong signal in PC-3 mock-transfected cells (controls).
PC-3 clones overexpressing AM (PC-AM15 and PC-AM32) show a less intense band. B: Bcl-2/Bax protein expression in PC-3 clones. Treatment of control cells
(PC-3 or PC-Mock2) with etoposide leads to decrease in Bcl-2 and increase in Bax levels, as compared to untreated cells. On the contrary, clones with high
expression of AM do not show such a dramatic change. C: Densitometric quantification of the bands, normalization with h-actin, and calculation of the ratio Bcl-2/
Bax. In control cells, Bcl-2/Bax ratio decreases after treatment with etoposide. However, such a decrease is not seen if cells overexpress AM.
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each cell type depending on the method of induction. AM
prevents apoptosis in DU 145 and PC-3 cells, but not in
LNCaP cells, after serum deprivation. However, when apopto-
sis is induced by etoposide, AM is a protective factor for PC-3
and LNCaP, but not for DU 145 cells. Thus, PC-3 cells seem to
be the type of cell line of choice to study the protective role of
AM in prostate cancer. We have previously found in cell
growth experiments that, unlike DU 145 cells, both PC-3 and
LNCaP cells respond similarly to AM when cells are cultured
in serum-enriched medium [13]. Dysruption of different
genetic pathways in these cells are likely to be responsible
for changes in cell growth and apoptosis responses after
exposure to AM. LNCaP cells have a wild type p53 and are
androgen sensitive; PC-3 cells are negative for p53 and are
androgen independent; DU 145 cells have a mutated p53, are
negative for Bax, and are insensitive to androgens as well [27].
We have shown here that etoposide causes increase in Baxlevels in parental PC-3 cells, but not in AM-overexpressing
cells. The functional alteration of Bax in DU 145 cells [28] can
explain why these cells are not protected by AM when treated
with etoposide.
Other studies have shown that AM plays a role in resistance
to induced apoptosis. Martinez et al. [29] demonstrated that
breast cancer cells that overexpressed AM are significantly less
prone to die through apoptosis, when serum is removed from
the culture medium. Resistance to apoptosis is related in these
cells to a decrease in the pro-apoptotic molecules Bax and BID,
and several caspases [29]. AM exerts an anti-apoptotic effect
on endothelial cells cultured in serum-free conditions [18].
Such an effect occurs via cGMP- and Bcl-independent
mechanisms [18]. Culture of endometrial cancer cells under
hypoxic conditions leads to programmed cell death, which is
prevented if cells are treated with or overexpress AM [17]. Bcl-
2 expression is induced more than 6-fold in these cells as a
consequence of AM treatment, regardless of whether the cells
I. Abasolo et al. / Regulatory Peptides 133 (2006) 115–122 121are cultured under hypoxia or normoxia conditions [17]. Bcl-2
and AM are co-expressed in cervical cancer [30]. Importantly,
in an in vivo rat model of ischemia and reperfusion, AM
attenuates myocardial infarction and apoptosis [31]. This effect
is caused through increase in Akt and Bad phosphorylation and
Bcl-2 levels [31]. Our present results in prostate cancer cells
also demonstrate that AM induces the expression of Bcl-2 and
decreases Bax, which favours the anti-apoptotic signaling and
prevents the cells from undergoing apoptosis.
Etoposide inhibits the activity of topoisomerase II thus
causing G2/M cell growth arrest and apoptosis [25]. Exposure
to etoposide results in double-stranded degradation of DNA,
which triggers the apoptotic cascade [25,26]. Although the
activation of ERK is usually related to cell survival and
proliferation, drugs that induce apoptosis can also produce
ERK activation [22,23]. The MAPK pathways (including ERK,
JNK and p38) have been reported to be activated by genotoxic
substances in many cell types [23,32]. Etoposide causes ERK1/
2 activation in U937 leukemia cells [22]. We have found in the
present study that levels of phosphorylated ERK1/2 increase in
parental PC-3 cells after treatment with etoposide. In PC-3 cells
overexpressing AM, phosphorylated ERK1/2 levels were lower
than levels of parental PC-3 cells, and treatment with etoposide
did not result in such an increase. This result also supports that
the genotoxic effect of etoposide is less effective if cells have
high expression of AM.
Taken together, all these data show that AM confers
resistance to agents that induce apoptosis, involving the Bcl-
family related signaling. In addition, AM expression is induced
by HIF-1a [33]. It is known that hypoxic areas of tumors are
refractory to radiation and chemotherapy [34]. In this regard,
AM could represent a putative tumor marker to predict response
to radio- or chemotherapy, although this possibility has not been
yet tested. AM also promotes tumor angiogenesis and enhances
VEGF [35], and MMP-2 [36] levels, and is highly expressed in
hypoxic tumors [37,38]. In renal cell carcinoma cells, hypoxia
leads to AM and VEGF expression, which act in a coordinate
way to facilitate cell growth [37]. All this could have
therapeutical implications in cancer treatment, since it seems
clear from different studies that AM provides resistance to stress
and induced-cell death. Although more confirmatory experi-
ments are needed, AM could represent a novel therapeutic target
for hypoxic and radio-chemo-resistant tumors.
As mentioned before, our previous work demonstrated a cell
growth inhibitory effect of AM in PC-3 and LNCaP cells
cultured in non-stressful conditions. On the contrary, if these
cells are subjected to stress (lack of serum or treatment with
etoposide) AM provides a survival advantage. These results
seem to be contradictory. However, it is possible that AM plays a
dual role in the control of cell growth depending upon the
external cell conditions. Other regulatory factors have demon-
strated to play a dual role in either cell cycle promotion or
induction of apoptosis, such as c-Myc [39]. This oncogene is a
nuclear phosphoprotein that functions as a transcription factor
stimulating both cell cycle progression and apoptosis. A ‘‘dual
signal’’ model has been prostulated to explain the ability of c-
Myc to drive cell division or apoptosis [40,41]. However, theprecise molecular mechanisms that induce these processes have
not yet been identified. The conditions of the extracellular
environment seem to be crucial in the function of c-Myc [41]. c-
Myc is activated by mitogenic signals to push cells into the G1
phase by activation of genes with a cell cycle promotion role and
suppression of genes involved in cell growth arrest. AM and c-
Myc are indeed related genes. AM induces the expression of
Max, a heterodimeric partner of c-Myc, which contributes to
rescue endothelial cells to suffer apoptosis [20]. The formation
ofMax–Max homodimers suppresses apoptosis [42]. As Oehler
et al. [17] pointed out, it is worth noticing that the anti-apoptotic
proteins AM, Bcl-2, and Max interact with c-Myc.
In summary, we have demonstrated that AM provides a
prostate cancer cell growth advantage against induced-
apoptosis. Because of the relationship between AM and
Bcl-2, their high expression in hormone independent prostate
cancer [7,43], and the role of AM in hypoxia and
angiogenesis [35], we suggest that AM should be taken into
consideration as a target for therapy. Hormone refractory
prostate cancer is often resistant to chemotherapeutic drugs,
such as etoposide, and Bcl-2 plays a key role in blocking the
pro-apoptotic cascades [44]. Clinical trials using etoposide are
currently underway to treat androgen-independent prostate
cancer. Designing strategies to sensitize prostate cancer cells
to etoposide or other chemotherapeutic agents could substan-
tially improve therapy. In this regard, inhibition of AM and
Bcl-2 may be relevant for androgen-independent prostate
cancer sensitization against chemotherapy.
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